Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Adamis Pharmaceuticals Corporation    ADMP

ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

Number of employees : 171 people.
Sales per Business
2019
USD (in Million)%
Pharmaceutical, Biotechnology and Other Drug Products22.11100%
Sales per region
20182019Delta
USD (in Million)%USD (in Million)%
United States15.09100%22.11100% +46.58%
Managers and Directors
NameAgeSinceTitle
Dennis J. Carlo, Dr.762009President, Chief Executive Officer & Director
Robert O. Hopkins602007Chief Financial Officer, Secretary & VP-Finance
Richard C. Williams762014Chairman
Ronald B. Moss, Dr.602017Chief Medical Officer
Karen K. Daniels672009Vice President-Operations
Howard C. Birndorf, Dr.702019Independent Director
Roshawn A. Blunt452019Independent Director
David J. Marguglio49-Director, Chief Business Officer & Senior VP
Mark Flather--Director-Investor Relations & Communications
Thomas H. Moll, Dr.542009Vice President-Research
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 134,721,125 133,445,844 99.1% 522,957 0.4% 99.1%
Shareholders
NameEquities%
Heights Capital Management, Inc. 4,918,972 5.25%
Anson Funds Management LP 3,013,054 3.22%
The Vanguard Group, Inc. 2,045,857 2.18%
683 Capital Management LLC 1,938,825 2.07%
Sio Capital Management LLC 1,935,961 2.07%
First Manhattan Co. 1,391,733 1.49%
BlackRock Fund Advisors 1,325,349 1.42%
Deka Investment GmbH 1,200,000 1.28%
Maven Investment Partners US Ltd. 1,000,000 1.07%
Geode Capital Management LLC 558,447 0.60%
Company contact information
Adamis Pharmaceuticals Corp.
11682 El Camino Real
Suite 300
San Diego, CA 92130

Phone : +1.858.997.2400
Web : http://www.adamispharmaceuticals.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Adamis Pharmaceuticals Corporation
Sector Other Pharmaceuticals
1st jan.Capitalization (M$)
ADAMIS PHARMACEUTICALS CORPORATION86.35%124
JOHNSON & JOHNSON-0.81%410 337
ROCHE HOLDING AG-1.63%274 753
PFIZER INC.-7.09%191 873
ABBVIE INC.-0.42%188 420
ELI LILLY AND COMPANY22.55%187 971
NOVARTIS AG-6.52%186 338
MERCK & CO., INC.-10.60%185 042
NOVO NORDISK A/S1.90%157 942
BRISTOL-MYERS SQUIBB COMPANY-4.34%135 392
AMGEN INC.-2.60%131 529
ASTRAZENECA PLC-6.38%124 268
SANOFI-1.68%115 133
GLAXOSMITHKLINE PLC-8.78%85 641
JIANGSU HENGRUI MEDICINE CO., LTD.-10.01%81 979
CHUGAI PHARMACEUTICAL CO., LTD.-18.15%68 397
BAYER AG7.13%60 380
DAIICHI SANKYO COMPANY, LIMITED-12.45%54 891
TAKEDA PHARMACEUTICAL COMPANY LIMITED0.08%54 273
ASTELLAS PHARMA INC.8.78%29 754
HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED-2.79%27 863